Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|August 17, 2022

Substance Use Disorder: A Brain Disease

Author(s)Brian Hurley, MD, MBA, DFASAM

Medication, counseling, and support—just as important in substance use disorder treatment as any other brain disease.

Brian Hurley, MD, MBA, DFASAM, gives a summary on his talk on medication treatment and psychotherapy for substance use disorders from the 2022 Annual Psychiatric Times™ World CME Conference.

Dr Hurley is the Medical Director of the Substance Abuse Prevention and Control at the Los Angeles County Department of Public Health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Kanisorn/Adobe Stock

Prescribing Benzodiazepines in Psychiatry, With Carl Salzman, MD

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 25th 2026

andranik123/Adobe Stock

Morning Rounds: August 17-23

ByJessica Walters

August 24th 2026

cannabis

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

August 20th 2026

opioids

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

ByChristian Heidbreder, PhD

August 20th 2026

drug testing

Let’s Talk About Drug Testing

ByEvan S. Schwarz, MD, FACEP, FACMT, FASAM

August 19th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

Exploitation of Individuals With Psychosis

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Prescribing Benzodiazepines in Psychiatry, With Carl Salzman, MD